Chimeric antigen receptor (CAR) T cell therapy is an arising and extremely promising cellular immunotherapy approach to treat cancer. This innovative approach takes advantage of the characteristics of T cells, which are a key component of our immune system. These T cells, hundreds of billions of which circulate through our bodies at any given time, are capable of detecting and destroying cells that have been damaged, infected with viruses, or malignant.

Is 2020 a year to forget? Most people may consider so.

This article presents two famous companies that profited from expert advice at critical moments

How to identify KOLs in your field based on their behavior, online presence, network size, and social media analysis.

2020 has tabled many unforeseen challenges as well as opportunities to the Life Science division, most notably of course, with the world population relying on services and solutions provided mostly by biotech and pharmaceutics enterprises. Nonetheless, along with the necessity of being skilled and prepared for facing new versions of the COVID 19, a demand for safer drugs, more liability, and greater value from the life science industry is heightening.

Identifying KOLs in life sciences is crucial for advancing research, but busy decision-makers often struggle with this task. Effective strategies include using online tools, attending events, collaborating with academic institutions, and defining research goals. Online platforms like PubMed, LinkedIn, and Twitter can provide valuable insights, while attending seminars and workshops allows networking opportunities. Academic institutions and research organizations are excellent sources for KOLs, and sponsoring research projects is an effective way to collaborate. Defining research goals ensures KOLs are selected based on specific project needs. By using these strategies, decision-makers can save costs, maximize results, and build relationships with KOLs and other stakeholders.